Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Filings indexed 788 across all filing types
Latest filing 2014-11-14 Board/Management Inform…
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 14, 2014, by Lipocine Inc. The key content is the announcement of the termination of employment of two senior officers: the Chief Technology Officer and the Corporate Business Development Officer. This clearly relates to changes in the company's board of directors or senior management. There are no financial statements or detailed financial data included, and the document is relatively short (2255 characters). Therefore, it is not an annual report, earnings release, or other financial report. The appropriate classification is Board/Management Information (MANG).
2014-11-14 English
Director's Dealing 2014
Director's Dealing
2014-11-14 English
Director's Dealing 2014
Director's Dealing
2014-11-13 English
Director's Dealing 2014
Director's Dealing
2014-11-13 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 10, 2014, by Lipocine Inc. It reports the issuance of a press release announcing financial and operational results for the third quarter of 2014. The document itself does not contain the financial results but references the press release as an exhibit. The length is 2342 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the rules, a short document announcing the release of financial results without containing the actual data should be classified as a Regulatory Filing (RNS), not as an Earnings Release (ER) or Interim Report (IR).
2014-11-10 English
10-Q
Interim / Quarterly Report Q3 2014
2014-11-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.